New Combinations of Boron Compounds and Adjuvants for the Treatment of Pathophysiological Conditions and Cancer and for Muscle Regeneration

A combination of a boron compound and an adjuvant for use in a method to induce myotube formation, increase myotube diameter and/or suppressed cell mortality in a mammal in need thereof;

• wherein the adjuvant comprises fibronectin or cell adhesion peptide domains, provided that when the adjuvant is fibronectin, the boron compound is not borax;
• wherein the cell adhesion peptide domain is a peptide which comprises or consists of a sequence selected from a list consisting of the SEQ ID NO:
• 1, SEQ ID NO:
• 2, SEQ ID NO:
• 3 SEQ ID NO:
• 4, SEQ ID NO:
• 5, SEQ ID NO:
• 6, SEQ ID NO:
• 7 and any combination thereof;
• and wherein when the adjuvant comprises fibronectin, the ratio of boron compound to the adjuvant is from 1.10−1 to 1.10−6 by weight and/or wherein when the adjuvant comprises cell adhesion peptide domains, the ratio by weight of boron compound to the adjuvant is from 10 to 10−6, preferably from 5 to 10−6 by weight.

A pharmaceutical composition comprising;

• a boron compound;
• at least an adjuvant which comprises fibronectin or cell adhesion peptide domains, provided that when the adjuvant is fibronectin, the boron compound is not borax;
• at least pharmaceutical acceptable excipient;
• wherein when the adjuvant comprises fibronectin, the ratio of boron compound to the adjuvant is from 1.10−1 to 1.10−6 by weight and/or wherein when the adjuvant comprises cell adhesion peptide domains, the ratio of boron compound to the adjuvant is from 10 to 10−6, preferably from 5 to 10−6;
• wherein the cell adhesion peptide domain is a peptide which comprises or consists of a sequence selected from a list consisting of the SEQ ID NO:
• 1, SEQ ID NO:
• 2, SEQ ID NO:
• 3, SEQ ID NO:
• 4;
• SEQ ID NO:
• 5;
• SEQ ID NO:
• 6, SEQ ID NO:
• 7 and any combination thereof.